Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Building R&D Capabilities In China – Spotlight On Pfizer

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Multinational pharmaceutical companies have moved beyond debating whether to open R&D operations in China to debating whether to open "brick and mortar" operations or "virtual" operations via outsourcing, according to speakers at the China 2008 Pharmaceutical R&D Summit in Shanghai

You may also be interested in...



Big Pharma Stretches To Reshape Itself To Enter Asia With Flexible, Multiple-Partner Networks – Singapore Conference

SINGAPORE - As big pharma looks across Asia for new ways of doing business, execs from the top pharma companies agreed that having people on the ground in Asia is critical and that companies are moving away from being fully integrated pharma companies to becoming fully integrated pharma networks

Big Pharma Stretches To Reshape Itself To Enter Asia With Flexible, Multiple-Partner Networks – Singapore Conference

SINGAPORE - As big pharma looks across Asia for new ways of doing business, execs from the top pharma companies agreed that having people on the ground in Asia is critical and that companies are moving away from being fully integrated pharma companies to becoming fully integrated pharma networks

GSK Jumps Into Growing China R&D Space

GlaxoSmithKline has joined a growing list of big pharma companies expanding in China, launching a research and development center based in Shanghai, the company announced May 24

Latest News
See All
UsernamePublicRestriction

Register

SC067852

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel